


Amendments to the Claims:

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-33 (canceled)

34. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (I):



(I)

wherein: X is -CHR₃-, -CHR₃-alkyl-, or -CHR₃-alkenyl-;

R₁ is selected from the group consisting of:

-alkenyl;

-aryl; and

-R₄-aryl;

R₂ is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;
-alkyl-Y-alkenyl;
-alkyl-Y-aryl; and
-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;
-halogen;
-N(R₃)₂;
-CO-N(R₃)₂;
-CO-C₁₋₁₀ alkyl;
-CO-O-C₁₋₁₀ alkyl;
-N₃;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl;

R₄ is alkyl or alkenyl, which may be interrupted by one or more

-O- groups;

each R₃ is independently H or C₁₋₁₀ alkyl;

Y is -O- or -S(O)₀₋₂;

n is 0 to 4; and


each R present is independently selected from the group consisting of C₁₋₁₀ alkyl,

C₁₋₁₀ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

35 (canceled)

36. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (II):



(II)

wherein

X is $-\text{CHR}_3-$, $-\text{CHR}_3\text{-alkyl-}$, or $-\text{CHR}_3\text{-alkenyl-}$;

R_{10} is selected from the group consisting of:

- H;
- alkyl;
- alkenyl; and
- aryl;

R_2 is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- heteroaryl;
- heterocyclyl;
- alkyl-Y-alkyl;
- alkyl-Y-alkenyl;
- alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

- OH;
- halogen;
- $-\text{N}(\text{R}_3)_2$;
- $-\text{CO}-\text{N}(\text{R}_3)_2$;

-CO-C₁₋₁₀ alkyl;
-CO-O-C₁₋₁₀ alkyl;
-N₃;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl;

n is 0 to 4;

Y is -O- or -S(O)₀₋₂;


each R₃ is independently H or C₁₋₁₀ alkyl; and

each R present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

37-39 (canceled)

40. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (III):



wherein: X is -CHR₃-, -CHR₃-alkyl-, or -CHR₃-alkenyl-;

R₁ is selected from the group consisting of:

- aryl;
- alkenyl; and
- R₄-aryl;

R₂ is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- heteroaryl;
- heterocyclyl;
- alkyl-Y-alkyl;
- alkyl-Y-aryl;
- alkyl-Y-alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

- OH;
- halogen;
- N(R₃)₂;
- CO-N(R₃)₂;
- CO-C₁₋₁₀ alkyl;
- CO-O-C₁₋₁₀ alkyl;
- N₃;
- aryl;
- heteroaryl;
- heterocyclyl;
- CO-aryl; and
- CO-heteroaryl;

R₄ is alkyl or alkenyl, which may be interrupted by one or more

-O- groups;

each R₃ is independently H or C₁₋₁₀ alkyl;

Y is $-\text{O}-$ or $-\text{S}(\text{O})_{0-2}-$;


n is 0 to 4; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

41-45 (canceled)

46. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula (IV):



(IV)

wherein: X is $-\text{CHR}_3-$, $-\text{CHR}_3\text{-alkyl-}$, or $-\text{CHR}_3\text{-alkenyl-}$;

R_{10} is selected from the group consisting of:

$-\text{H}$;

$-\text{alkyl}$;

$-\text{alkenyl}$; and

$-\text{aryl}$;

R_2 is selected from the group consisting of:

$-\text{hydrogen}$;

$-\text{alkyl}$;

$-\text{alkenyl}$;

$-\text{aryl}$;

$-\text{heteroaryl}$;

-heterocyclyl;
-alkyl-Y-alkyl;
-alkyl-Y-aryl;
-alkyl-Y- alkenyl; and
-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;
-halogen;
-N(R₃)₂;
-CO-N(R₃)₂;
-CO-C₁₋₁₀ alkyl;
-CO-O-C₁₋₁₀ alkyl;
-N₃;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl;

each R₃ is independently H or C₁₋₁₀ alkyl;

Y is -O- or -S(O)₀₋₂;


n is 0 to 4; and

each R present is independently selected from the group consisting of C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

47-49 (canceled)

50. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (IV):



(IV)

wherein: X is $-\text{CHR}_3-$, $-\text{CHR}_3\text{-alkyl-}$, or $-\text{CHR}_3\text{-alkenyl-}$;

R_{10} is selected from the group consisting of:

- H;
- alkyl;
- alkenyl; and
- aryl;

R_2 is selected from the group consisting of:

- hydrogen;
- alkyl;
- alkenyl;
- aryl;
- heteroaryl;
- heterocyclyl;
- alkyl-Y-alkyl;
- alkyl-Y-aryl;
- alkyl-Y-alkenyl; and
- alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

- OH;
- halogen;
- $-\text{N}(\text{R}_3)_2$;

-CO-N(R₃)₂;
-CO-C₁₋₁₀ alkyl;
-CO-O-C₁₋₁₀ alkyl;
-N₃;
-aryl;
-heteroaryl;
-heterocyclyl;
-CO-aryl; and
-CO-heteroaryl;

each R₃ is independently H or C₁₋₁₀ alkyl;

Y is -O- or -S(O)₀₋₂-;

n is 0 to 4; and

each R present is independently selected from the group consisting of C₁₋₁₀ alkyl,

C₁₋₁₀ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.